Publications by authors named "Warren Skoza"
Article Synopsis
- * In a study involving 1,421 patients monitored for about 6 years, those receiving AVR showed significantly lower risks for both all-cause and cardiovascular mortality compared to those who were managed with clinical surveillance.
- * The benefits of AVR were particularly evident in patients with preserved left ventricular ejection fraction (LVEF ≥50%), as they also showed improvements in heart function over time.
Many patients with chronic kidney disease have chronically elevated cardiac troponin levels, and if they present with symptoms suggesting an acute coronary syndrome, it is often difficult to determine if this is the correct diagnosis. This article briefly reviews the major challenges in diagnosing acute coronary syndrome in patients with chronic kidney disease, describes the mechanisms and prognostic significance of troponin elevation in chronic kidney disease, and provides a diagnostic algorithm to risk-stratify patients with chronic kidney disease who have troponin elevation and suspected acute coronary syndrome.
View Article and Find Full Text PDFBackground: Patients with severe tricuspid regurgitation (TR) exhibit high morbidity and mortality. Tricuspid transcatheter edge-to-edge repair (T-TEER) is a rapidly evolving strategy to address the unmet clinical need of severe TR therapies.
Objective: Organize the current body of evidence on outcomes following use of the PASCAL (Edwards Lifesciences) system for T-TEER.
Background: Immune checkpoint inhibitors can result in overlap syndrome comprised of myasthenia gravis, myositis and myocarditis. However, the mortality predictors have not been clearly delineated.
Methods: We examined the characteristics of 11 patients diagnosed with overlap syndrome at Cleveland Clinic.
The pharmacologic management of heart failure with preserved ejection fraction (HFpEF) involves far fewer options with demonstrated additional benefit. Therefore, we examined the effect of combination of multiple classes of HF medication in the 30-day hospital readmission in patients with HFpEF. All adult patients discharged with a diagnosis of HFpEF and a left ventricular ejection fraction (LVEF) of ≥ 50% reported during the admission or within the previous six months from our institution were retrospectively studied for a 30-day hospital readmission risk.
View Article and Find Full Text PDF